Omeros (NASDAQ:OMER) Announces Earnings Results

Omeros (NASDAQ:OMER – Get Free Report) posted its earnings results on Monday. The biopharmaceutical company reported $0.06 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.02 by $0.04, Zacks reports.

Here are the key takeaways from Omeros’ conference call:

  • YARTEMLEA sales continued to grow: Third-quarter gross sales rose 30% sequentially to $41.8 million and net sales increased 26% to $35.9 million. Management said momentum continued into the fourth quarter.
  • Commercial adoption and reimbursement access expanded: 109 accounts had ordered YARTEMLEA by quarter-end, up from 73 in June, and 80% of the top 40 U.S. transplant centers had approved it through their P&T committees. The company highlighted the new Medicare inpatient payment and outpatient reimbursement status as potential adoption advantages.
  • Omeros reported $13.3 million in operating cash flow for a second consecutive quarter and ended September with $95.3 million in cash and investments. GAAP results were a $57.4 million net loss, largely reflecting a $62 million non-cash mark-to-market loss; adjusted net income was $4.7 million.
  • European regulators issued a negative opinion on the narsoplimab marketing application for TA-TMA, and Omeros plans to stop accepting new patients into its European compassionate-use program. The company said it is pursuing approvals in other countries and reimbursed named-patient access programs.
  • The company plans to broaden YARTEMLEA development, with studies in hyperinflammatory ARDS and prevention of pediatric TA-TMA expected to start around year-end or early 2027. Separately, an animal-study delay pushed the planned start of the OMS527 cocaine-use-disorder trial to early 2027.

Omeros Stock Down 4.6%

OMER stock traded down $0.81 during trading on Monday, reaching $16.68. The company’s stock had a trading volume of 1,509,644 shares, compared to its average volume of 1,596,204. The company’s fifty day moving average is $18.27 and its 200-day moving average is $13.74. The company has a market capitalization of $1.21 billion, a P/E ratio of 13.03 and a beta of 2.96. Omeros has a 1 year low of $6.70 and a 1 year high of $21.24.

Insiders Place Their Bets

In related news, Director Arnold C. Hanish sold 10,000 shares of Omeros stock in a transaction that occurred on Thursday, August 27th. The stock was sold at an average price of $18.95, for a total transaction of $189,500.00. Following the sale, the director owned 5,000 shares of the company’s stock, valued at approximately $94,750. This trade represents a 66.67% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Thomas J. Cable sold 15,000 shares of the business’s stock in a transaction that occurred on Thursday, August 20th. The stock was sold at an average price of $18.45, for a total value of $276,750.00. Following the completion of the transaction, the director directly owned 35,067 shares in the company, valued at approximately $646,986.15. This represents a 29.96% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders sold 100,906 shares of company stock worth $1,904,955. 10.50% of the stock is currently owned by insiders.

Analyst Ratings Changes

A number of equities research analysts have weighed in on OMER shares. Weiss Ratings upgraded shares of Omeros from a “hold (c-)” rating to a “hold (c)” rating in a research note on Thursday, October 8th. Cantor Fitzgerald reissued an “overweight” rating and issued a $22.00 target price on shares of Omeros in a research report on Wednesday, October 14th. Wall Street Zen upgraded Omeros from a “hold” rating to a “buy” rating in a research note on Saturday, August 15th. Finally, HC Wainwright reaffirmed a “buy” rating on shares of Omeros in a research report on Monday, July 27th. Three research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $30.33.

Get Our Latest Stock Analysis on Omeros

Omeros Company Profile

(Get Free Report)

Omeros Corporation (NASDAQ: OMER) is a biopharmaceutical company focused on discovering, developing and commercializing therapies for disorders involving the complement, immune and coagulation systems. The company has also developed a pipeline of investigational therapies aimed at treating serious diseases involving complement activation and immune-system dysfunction. The company is headquartered in Seattle, Washington, and was founded in 1994. Its leading investigational programs have included narsoplimab, which targets the lectin pathway of the complement system, and OMS906, an antibody designed to inhibit MASP-3 and regulate the alternative pathway.

Read More

Earnings History for Omeros (NASDAQ:OMER)

Receive News & Ratings for Omeros Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omeros and related companies with MarketBeat.com's FREE daily email newsletter.